| First Author | Mei W | Year | 2025 |
| Journal | Cell | Volume | 188 |
| Issue | 2 | Pages | 371-389.e28 |
| PubMed ID | 39657676 | Mgi Jnum | J:361350 |
| Mgi Id | MGI:7856356 | Doi | 10.1016/j.cell.2024.11.009 |
| Citation | Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. Cell 188(2):371-389.e28 |
| abstractText | Identifying patients at risk for metastatic relapse is a critical medical need. We identified a common missense germline variant in proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) that is associated with reduced survival in multiple breast cancer patient cohorts. Genetic modeling of this gain-of-function single-nucleotide variant in mice revealed that it causally promotes breast cancer metastasis. Conversely, host PCSK9 deletion reduced metastatic colonization in multiple breast cancer models. Host PCSK9 promoted metastatic initiation events in lung and enhanced metastatic proliferative competence by targeting tumoral low-density lipoprotein receptor related protein 1 (LRP1) receptors, which repressed metastasis-promoting genes XAF1 and USP18. Antibody-mediated therapeutic inhibition of PCSK9 suppressed breast cancer metastasis in multiple models. In a large Swedish early-stage breast cancer cohort, rs562556 homozygotes had a 22% risk of distant metastatic relapse at 15 years, whereas non-homozygotes had a 2% risk. Our findings reveal that a commonly inherited genetic alteration governs breast cancer metastasis and predicts survival-uncovering a hereditary basis underlying breast cancer metastasis. |
